Image classification, a pivotal task in multiple industries, faces computational challenges due to the burgeoning volume of visual data. This research addresses these challenges by introducing two quantum machine learning models that leverage the principles of quantum mechanics for effective computations. Our first model, a hybrid quantum neural network with parallel quantum circuits, enables the execution of computations even in the noisy intermediate-scale quantum era, where circuits with a large number of qubits are currently infeasible. This model demonstrated a record-breaking classification accuracy of 99.21% on the full MNIST dataset, surpassing the performance of known quantum–classical models, while having eight times fewer parameters than its classical counterpart. Also, the results of testing this hybrid model on a Medical MNIST (classification accuracy over 99%), and on CIFAR-10 (classification accuracy over 82%), can serve as evidence of the generalizability of the model and highlights the efficiency of quantum layers in distinguishing common features of input data. Our second model introduces a hybrid quantum neural network with a Quanvolutional layer, reducing image resolution via a convolution process. The model matches the performance of its classical counterpart, having four times fewer trainable parameters, and outperforms a classical model with equal weight parameters. These models represent advancements in quantum machine learning research and illuminate the path towards more accurate image classification systems.
Cancer is one of the leading causes of death worldwide. It is caused by various genetic mutations, which makes every instance of the disease unique. Since chemotherapy can have extremely severe side effects, each patient requires a personalized treatment plan. Finding the dosages that maximize the beneficial effects of the drugs and minimize their adverse side effects is vital. Deep neural networks automate and improve drug selection. However, they require a lot of data to be trained on. Therefore, there is a need for machine-learning approaches that require less data. Hybrid quantum neural networks were shown to provide a potential advantage in problems where training data availability is limited. We propose a novel hybrid quantum neural network for drug response prediction based on a combination of convolutional, graph convolutional, and deep quantum neural layers of 8 qubits with 363 layers. We test our model on the reduced Genomics of Drug Sensitivity in Cancer dataset and show that the hybrid quantum model outperforms its classical analog by 15% in predicting drug effectiveness values. The proposed hybrid quantum machine learning model is a step towards deep quantum data-efficient algorithms with thousands of quantum gates for solving problems in personalized medicine, where data collection is a challenge.
22 May 2024 in Machine Learning: Science and Technology
Finding the distribution of the velocities and pressures of a fluid by solving the Navier–Stokes equations is a principal task in the chemical, energy, and pharmaceutical industries, as well as in mechanical engineering and in design of pipeline systems. With existing solvers, such as OpenFOAM and Ansys, simulations of fluid dynamics in intricate geometries are computationally expensive and require re-simulation whenever the geometric parameters or the initial and boundary conditions are altered. Physics-informed neural networks (PINNs) are a promising tool for simulating fluid flows in complex geometries, as they can adapt to changes in the geometry and mesh definitions, allowing for generalization across fluid parameters and transfer learning across different shapes. We present a hybrid quantum PINN (HQPINN) that simulates laminar fluid flow in 3D Y-shaped mixers. Our approach combines the expressive power of a quantum model with the flexibility of a PINN, resulting in a 21% higher accuracy compared to a purely classical neural network. Our findings highlight the potential of machine learning approaches, and in particular HQPINN, for complex shape optimization tasks in computational fluid dynamics. By improving the accuracy of fluid simulations in complex geometries, our research using hybrid quantum models contributes to the development of more efficient and reliable fluid dynamics solvers.
Powerful hardware services and software libraries are vital tools for quickly and affordably designing, testing, and executing quantum algorithms. A robust large‐scale study of how the performance of these platforms scales with the number of qubits is key to providing quantum solutions to challenging industry problems. This work benchmarks the runtime and accuracy for a representative sample of specialized high‐performance simulated and physical quantum processing units. Results show the QMware simulator can reduce the runtime for executing a quantum circuit by up to 78% compared to the next fastest option for algorithms with fewer than 27 qubits. The Amazon Web Service State‐Vector Simulator 1 offers a runtime advantage for larger circuits, up to the maximum 34 qubits. Beyond this limit, QMware can execute circuits as large as 40 qubits. Physical quantum devices, such as Rigetti's Aspen‐M2, can provide an exponential runtime advantage for circuits with more than 30 qubits. However, the high financial cost of physical quantum processing units presents a serious barrier to practical use. Moreover, only IonQ's Harmony quantum device achieves high fidelity with more than four qubits. This study paves the way to understanding the optimal combination of available software and hardware for executing practical quantum algorithms.
In the realm of liver transplantation, accurately determining hepatic steatosis levels is crucial. Recognizing the essential need for improved diagnostic precision, particularly for optimizing diagnosis time by swiftly handling easy-to-solve cases and allowing the expert time to focus on more complex cases, this study aims to develop cutting-edge algorithms that enhance the classification of liver biopsy images. Additionally, the challenge of maintaining data privacy arises when creating automated algorithmic solutions, as sharing patient data between hospitals is restricted, further complicating the development and validation process. This research tackles diagnostic accuracy by leveraging novel techniques from the rapidly evolving field of quantum machine learning, known for their superior generalization abilities. Concurrently, it addresses privacy concerns through the implementation of privacy-conscious collaborative machine learning with federated learning. We introduce a hybrid quantum neural network model that leverages real-world clinical data to assess non-alcoholic liver steatosis accurately. This model achieves an image classification accuracy of , surpassing traditional methods by . Moreover, by employing a federated learning approach that allows data from different clients to be shared while ensuring privacy, we maintain an accuracy rate exceeding . This initiative marks a significant step towards a scalable, collaborative, efficient, and dependable computational framework that aids clinical pathologists in their daily diagnostic tasks.
13 June 2024 in IEEE Transactions on Quantum Engineering
The drug design process currently requires considerable time and resources to develop each new compound that enters the market. This work develops an application of hybrid quantum generative models based on the integration of parametrized quantum circuits into known molecular generative adversarial networks, and proposes quantum cycle architectures that improve model performance and stability during training. Through extensive experimentation on benchmark drug design datasets, QM9 and PC9, the introduced models are shown to outperform the previously achieved scores. Most prominently, the new scores indicate an increase of up to 30% in the quantitative estimation of druglikeness. The new hybrid quantum machine learning algorithms, as well as the achieved scores of pharmacokinetic properties, contribute to the development of fast and accurate drug discovery processes.